Gorham–Stout disease: good results of bisphosphonate treatment in 6 of 7 patients

Kristian Nikolaus SCHNEIDER 1, Max MASTHOFF 2, Georg GOSHEGER 1, Sebastian KLINIEGBEL 1, Dominik SCHORN 1, Julian RÖDER 1, Tim VOGLER 1, Moritz WILDGRUBER 2, and Dimosthenis ANDREOU 1

1 Department of Orthopaedics and Tumor Orthopaedics, University Hospital of Münster, Germany; 2 Institute of Clinical Radiology, University Hospital of Münster, Germany

Correspondence: kristian.schneider.mh@gmail.com
Submitted 2019-09-05. Accepted 2019-12-16.

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of the Nordic Orthopedic Federation. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI 10.1080/17453674.2019.1709716

Gorham–Stout disease (GSD) is a rare mono- or polyostotic condition characterized by idiopathic intraosseous proliferation of angiomatous structures resulting in progressive destruction and resorption of bone. Little is known about the course of disease and no previous study has evaluated patients’ quality of life (QoL).

Patients and methods — This is a retrospective analysis of 7 consecutive patients (5 males) with a median age at diagnosis of 14 years and a median follow-up of 7 years who were diagnosed with GSD in our department between 1995 and 2018. Data regarding clinical, radiographic, and histopathological features, and treatment, as well as sequelae and their subsequent therapy, were obtained. QoL was assessed by Musculoskeletal Tumor Society Score (MSTS), Toronto Extremity Salvage Score (TESS), and Reintegration to Normal Living (RNL) Index.

Results — 3 patients had a monoostotic and 4 patients a polyostotic disease. Besides a diagnostic biopsy, 4 of the 7 patients had to undergo 8 surgeries to treat evolving sequelae. Using an off-label therapy with bisphosphonates in 6 patients, a stable disease state was achieved in 5 patients after a median of 20 months. The median MSTS, TESS, and RNL Index at last follow-up was between 87% and 79%.

Interpretation — Due to its rare occurrence, diagnosis and treatment of GSD remain challenging. Off-label treatment with bisphosphonates appears to lead to a stable disease state in the majority of patients. QoL varies depending on the individual manifestations but good to excellent results can be achieved even in complex polyostotic cases with a history of possibly life-threatening sequelae.
Patients and methods

7 consecutive patients (5 males) who were diagnosed with GSD in our department between 1995 and 2018 were included in this study. All patients were symptomatic and/or had documented disease progression. Anonymized pertinent data were obtained from patients’ records. Patients’ quality of life at last follow-up was determined using a combination of standardized scoring systems, as proposed by Tunn et al. (2008): Musculoskeletal Tumor Society Score (MSTS), Toronto Extremity Salvage Score (TESS), and Reintegration to Normal Living (RNL) Index.

The median age at diagnosis was 14 years (5–42) and the median follow-up amounted to 7 years (1–22). The median time from first symptoms to final diagnosis was 27 months (3–60). All patients complained of local pain without history of previous trauma, combined with local swelling in 3 cases, restricted range of movement in 1, case and weight loss in another case. 4 patients had a polyostotic and 3 patients a monoostotic disease (Table 1). The diagnosis was histopathologically confirmed in all patients. Biopsies showed dilated thin-walled lymphatic and vascular vessels within rarefied lamellar bone (Figure 1).

Results

Local surgical treatment was required in 4 patients (Table 2). 1 patient underwent plate fixation after a femoral fracture (Figure 2), while another patient required occipitocervical fusion due to a progressive atlantoaxial instability (Figure 3). A stabilizing spinal instrumentation (T6–L4) was necessary in a third patient due to progressive kyphosis. The same patient required further surgical treatment 4 years later due to progressive osteolysis of T11 and L5 leading to cerebrospinal fluid leaks. Another revision surgery was necessary 5 years later following a rod fracture due to material fatigue. The remaining patient suffered from recurrent erysipelas in his left leg, which was severely deformed from the disease (Figure 4). During an erysipelas bout he developed a life-threatening sepsis, which rendered a knee disarticulation necessary.

2 patients developed a chylothorax 4 and 14 years after initial diagnosis, respectively (Figure 5). Surgical treatment with pleurodesis followed by pleurectomy was required in one of these patients due to progressive respiratory distress, while the other patient remains asymptomatic with a stable chylothorax for over 5 years. No patient underwent radiation treatment.

6 patients received bisphosphonate therapy, which was contraindicated in the remaining patient due to a severe

Table 1. Clinical data of 7 patients with GSD

| Patient | Sex | Age diagnosed | Follow-up | Initial symptoms | Involved bones |
|---------|-----|---------------|-----------|------------------|----------------|
| 1       | Male | 5y7m          | 7y3m      | Pain, swelling   | Skull, thoracic and lumbar vertebrae, ribs, RL pelvis, RL femur, RL humerus |
| 2       | Female | 29y1m        | 9y3m      | Pain             | R ilium |
| 3       | Male | 21y2m         | 2y3m      | Pain, swelling   | RL femur, L pelvis, R humerus, thoracic and lumbar vertebrae |
| 4       | Male | 13y8m         | 21y10m    | Pain             | Thoracic and lumbar vertebrae, sternum, RL pelvis, R humerus |
| 5       | Female | 11y7m        | 8m        | Pain, swelling   | L tibia |
| 6       | Male | 42y7m         | 6y10m     | Pain, shoulder impingement | L scapula |
| 7       | Male | 12y4m         | 4y7m      | Pain, weight loss | Cervical vertebrae |
nephropathy (Table 2). No adverse effects were observed under bisphosphonate treatment. Stable disease (defined as no radiographic progression of bone resorption) was achieved in 5 patients after a median of 20 months (8–42). 1 patient has been under bisphosphonate treatment for only 2 months with no radiographic follow-up as yet. 2 patients with chylothorax underwent an additional treatment with sirolimus and 1 patient an initial IFNa-2b therapy that had to be discontinued due to hyperthyreosis after 12 months of treatment (Table 2).

The median MSTS at last follow-up amounted to 87% (23–97); the median TESS was 87% (43–97) while the median RNL Index amounted to 79% (39–88). Although the small number of cases in our cohort precluded the use of statistical analyses, we observed that younger patients tended to achieve better score results than patients aged 18 years and older, while male patients fared slightly better than female patients. On the other hand, we found that patients with a monoostotic and polyostotic disease had similar scores. The 2 patients who developed a chylothorax had a somewhat lower MSTS but a similar TESS and RNL Index compared with the patients without chylothorax. Good to excellent results in all 3 QoL scores were achieved in the 6 patients who received bisphosphonates whilst poor results were obtained in the patient who was not able to undergo bisphosphonate treatment (Table 3).

Discussion

GSD is a rare disease and severe symptoms have been described at presentation, such as bone deformities, patho-

---

Table 2. Clinical data of 7 patients with GSD

| Patient | A | B | C | Medication | D | Chylothorax |
|---------|---|---|---|------------|---|-------------|
| 1       | 3m| 1m| 12m| 09/11—today: zoledronic acid 2 mg every 4 weeks until 03/18, since 03/18: every 6 weeks | Plate osteosynthesis due to pathologic fracture L (5y5m) | R 4y after GSD diagnosis |
|         | 02/10—today: cholecalciferol 1–2 x 1000 IE daily | | | 07/17 sirolimus 0.5 mg x 2 daily | -> discontinued due to recurrent aphthous ulcerations |
|         | 07/15—09/17 propranolol 1 mg per kg of body weight | | | -> discontinued due to bradycardia |
| 2       | 2y| 18m| 20m| 12/10—06/11 zoledronic acid 4 mg every 4 weeks | – | – |
| 3       | 5y| – | | Due to a severe nephropathy, bisphosphonate treatment is currently contraindicated in this patient | L knee disarticulation due to recurrent erysipelas and sepsis (0m) | – |
| 4       | 3y| 13y10m| 3y6m| 09/09—09/10 peginterferon alpha2b 50µg every week | Spinal instrumentation (T6–L4) (12y7m) | L 14y after GSD diagnosis |
|         | -> discontinued due to hyperthyreosis | | 09/10—06/12 sirolimus 1 mg daily | Augmented closure of cerebrospinal fluid leaks T11 and L5 (16y3m) |
|         | 01/13—today: sirolimus 1–2 mg daily | | 02/10—today: zoledronic acid 4 mg every 4 weeks | Revision surgery after after rod fracture in (22y) |
|         | -> discontinued due to progressive chylothorax | 02/10—02/17: zoledronic acid 4 mg every 4 weeks | 02/10—02/17: cholecalciferol 1–2 x 1000 IE daily | |
|         | 02/10—02/17: Ca 2 x 500mg for 10d after zoledronic acid IV | | | |
| 5       | 3m| 1m| – | 02/18—today: zoledronic acid 2 mg every 4 weeks | – | – |
| 6       | 3y| 1m| 8m | 01/12—today: alendronic acid 70 mg every week | – | – |
| 7       | 2y| 1m| 20m| 03/14—today: zoledronic acid 4mg every 4 weeks | Occipitocervical fusion (O–C2) due to atlantoaxial instability (8m) | – |

A. Time from first symptoms until diagnosis.  
B. Time from diagnosis until start of medication.  
C. Time of medication until stable disease.  
D. Required surgery (time after initial diagnosis).  
*Chylothorax surgery: pleurodesis 10/2011, pleurectomy 03/2015

Table 3. Median values of QoL scores of 7 patients with GSD

|                      | MSTS | TESS | RNL index |
|----------------------|------|------|-----------|
| Male sex             | 87   | 93   | 85        |
| Female sex           | 83   | 85   | 77.5      |
| < 18 years old       | 93   | 93   | 85        |
| > 18 years old       | 77   | 84.5 | 77        |
| Monoostotic disease  | 87   | 87   | 79        |
| Polyostotic disease  | 80   | 87.5 | 80        |
| No bisphosphonate treatment | 23  | 43   | 39        |
| Bisphosphonate treatment | 90  | 90   | 82        |

MSTS – Musculoskeletal Tumor Society Score  
TESS – Toronto Extremity Salvage Score  
RNL – Reintegration to Normal Living
logic fractures, or neurological deficits due to vertebral osteolysis (Kulenkampff et al. 1990). However, most patients appear to initially develop unspecific symptoms such as pain, regional swelling, or a restricted range of motion (Möller et al. 1999, Patel 2005, Dellinger et al. 2014, Agyeman et al. 2017). We have observed similar initial symptoms in our patients as well (Table 1). As a result, medical consultation, imaging studies and diagnosis may be delayed, with only 2 of our patients being diagnosed within 3 months after developing complaints.
Due to disease progression and local symptoms, 6 of our 7 patients underwent bisphosphonate treatment, and 5 of them achieved radiologically stable disease, while treatment was only recently started in the remaining patient. Several case reports have demonstrated the clinical benefit from bisphosphonates (Mignogna et al. 2005, Yerganyan et al. 2015, Brance et al. 2019). Hagberg et al. (1997) reported the first successful treatment of GSD with bisphosphonates. Following an unsuccessful radiation treatment, they initiated a bisphosphonate treatment with clodronic acid in combination with IFNa-2b in a 19-year-old male patient who suffered from progressive, polyostotic disease with a chylothorax, and achieved a “rapid improvement” of the patient’s general condition. Hammer et al. (2005) later reported that bisphosphonate monotherapy in GSD resulted in an “immediate clinical improvement” and radiologically stable disease within two years in a 45-year-old woman.

Despite the activity and clinical benefits in GSD, various possible adverse effects of bisphosphonate treatment have been described. Besides gastrointestinal intolerance, flu-like symptoms (after intravenous application) and the development of osteonecrosis of the jaw (ONJ) have been described (Reid 2011, Wessel et al. 2008). Despite the fact that we have administered a frequent bisphosphonate regime to the majority of patients and the average treatment duration amounted to over 4 years, none of our patients developed an ONJ or other relevant adverse effects in long-term follow-up. Informed consent to off-label usages is required as bisphosphonates are not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for treatment of GSD (Dellinger et al. 2014).

Another treatment option for GSD patients reported in the literature is sirolimus, an mTOR inhibitor that acts as a down-regulator of cellular proliferation and angiogenesis (García et al. 2016). García et al. (2016) described a successful sirolimus treatment in a 43-year-old female patient with GSD of her left hemithorax accompanied by a left-sided chylothorax. Despite achieving remission within 4 weeks, treatment had to be discontinued due to metrorrhagia. We initiated sirolimus treatment additionally to bisphosphonate treatment in our 2 patients who developed a chylothorax. However, 1 patient developed recurrent aphthous ulcerations that required discontinuation of the treatment, while the other patient’s chylothorax progressed under treatment and required surgery. In the first patient, the chylothorax remains asymptomatic and stable, so that the sirolimus treatment was not resumed.

Due to its antiangiogenic effect, treatment with IFNa-2b is also an effective treatment option in GSD. As with sirolimus, IFNa-2b is frequently used as combination therapy with bisphosphonates (Hagberg et al. 1997, Kuriyama et al. 2010, Ramaroli et al. 2019). We initiated IFNa-2b monotherapy in our very first patient. After reports of the effect of bisphosphonate treatment in GSD, we later opted for combination therapy with bisphosphonates and IFNa-2b. Due to the development of a severe hyperthyreosis, the IFNa-2b treatment had to be discontinued. As stable disease was achieved under bisphosphonate monotherapy, the IFNa-2b treatment was not resumed.

Regarding local treatment options, several authors have reported on the effectiveness of radiotherapy in GSD (Kulenkampff et al. 1990, Dunbar et al. 1993, Rauh and Gross 1997, Heyd et al. 2011, Yerganyan et al. 2015). Considering the relatively young age of GSD patients at diagnosis as well as the late effects of radiotherapy, including particularly the risk for secondary malignancies, we preferred to avoid radiotherapy in our patients.

Surgical treatment may be required in GSD patients both for the affected bones and for possible sequelae (Patel 2005). In the long bones, most authors recommend resection followed by reconstruction or endoprosthetic replacement in weight-bearing bones (Turra et al. 1990, Chan et al. 2016, Ellati et al. 2016, Liu et al. 2018). Spinal stabilization surgery may be required in patients with spinal involvement and actual or impending neurological deficits. 2 of our patients required stabilization procedures, with one of them undergoing 2 further surgeries due to disease progression with development of cerebrospinal fluid leaks and material fatigue. Surgery might also be required in patients who develop a chylothorax—a potentially life-threatening sequela of GSD with a reported incidence of about 17% and a mortality of up to 34% (Patrick 1976, Tie et al. 1994, Ludwig et al. 2016).

A novel finding of our study concerns the QoL of affected patients. To our knowledge, no study has previously evaluated this aspect of GSD. Good to excellent MSTS, TESS, and RNL Index scores were achieved in all patients undergoing bisphosphonate treatment. Indeed, the only patient with very poor results in our cohort was the one with a contraindication to medical treatment due to a severe nephropathy, providing further evidence to the observation that systematic treatment leads to a rapid relief of symptoms (Hagberg et al. 1997).

Another somewhat surprising finding was that the patient-reported TESS and RNL Index were similar in patients with mono- and polyostotic disease, as well as in patients with and without sequelae (Table 3). We also found that younger patients tended to have higher QoL scores compared with older patients. This fact has also been observed by other authors and could be attributed to better adaptation to the disease by younger patients who grow up with it and cope better with the subsequent impairments and disabilities (Tunn et al. 2008, Heaver et al. 2016).

The low number of patients in our cohort is, naturally, a limitation of our study. However, among the approximately 300 cases reported, up to now, in the literature, our cohort represents one of the largest series treated at a single institution, reflecting the low incidence of GSD and the challenges of accruing large patient numbers.

In conclusion, due to its rare occurrence, diagnosis and treatment of GSD remain challenging. Off-label treatment...
with bisphosphonates appears to lead to a stable disease state in the majority of patients.

**Ethics, funding, and potential conflicts of interest**

The study was approved by our local ethics committee Ethik-Kommission, Ärztekammer Westfalen-Lippe. Reference number: 2018–617–f–S. The authors received no specific funding for this work. The authors declare that they have no competing interests.

The authors acknowledge support from the Open Access Publication Fund of the University of Münster/Germany.

**Acta** thanks Jendrik Hardes and Ulrich Exner for help with peer review of this study.

Adams D M, Trener C C, Hammill A M, Vinks A A, Patel M N, Chaudry G, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics 2016; 137(2): e20153257-72.

Agyeman K, Pretell-Mazzini J, Subhawong T, Kerr DA, Jose J. Gorham disease. Am J Orthop 2017; 46(6): E458-62.

Boyer P, Bourgeois P, Boyer O, Catoton G, Saillant G. Massive Gorham–Stout syndrome of the pelvis. Clin Rheumatol 2005; 24(5): 551-5.

Brance M L. Two cases of Gorham–Stout disease with good response to zolendronic acid treatment. CCMBM 2017; 14(2): 250-4.

Chan C K, Mohamed R-M, Azlina A A, Azhar M M. Multicentric disappearing bone disease treated with arthroplasty. Malays Orthop J 2016; 10(3): 42-5.

Dellinger M T, Garg N, Olsen B R. Viewpoints on vessels and vanishing bones in Gorham–Stout disease. Bone 2014; 63(C): 47-52.

Dunbar S F, Rosenberg A, Mankin H, Rosenthal D, Suit H D. Gorham’s massive osteolysis: the role of radiation therapy and a review of the literature. Int J Radiat Oncol Biol Phys 1993; 26(3): 491-7.

Ellati R, Attili A, Haddad H, Al-Hussaini M, Shehadeh A. Novel approach of treating Gorham–Stout disease in the humerus: case report and review of literature. Eur Rev Med Pharmacol Sci 2016; 20(3): 426-32.

García V, Alonso-Claudio G, Gómez-Hernández M-T, Chamorro A-J. Case report: Sirolimus on Gorham–Stout disease. Colomb Med Universidad del Valle; 2016; 47(4): 213-16.

Gorham L W, Stout A P. Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone): its relation to hemangiomasis. J Bone Joint Surg Am 1955; 37-A(5): 985-1004.

Hagberg H, Lamberg K, Aström G. Alpha-2b interferon and oral clodronate for Gorham’s disease. Lancet 1997; 350(9094): 1822-3.

Hammer F, Kenn W, Wesselmann U, Hofbauer L C, Delling G, Alloio B, et al. Gorham–Stout disease: stabilization during bisphosphonate treatment. J Bone Miner Res 2005; 20(2): 350-3.

Heaver C, Isaacson A, Gregory J J, Cribb G, Cool P. Patient factors affecting the Toronto extremity salvage score following limb salvage surgery for bone and soft tissue tumors. J Surg Oncol 2016;113(7): 804-10.

Heyd R, Rabeneck D, Dörnrenburg O, Tsels N, Zamboglou N. Gorham–Stout syndrome of the pelvic girdle treated by radiation therapy: a case report. Strahlenther Onkol 2011; 187(2): 140-3.

Kulenkampff H A, Richter G M, Hasse W E, Adler C P. Massive pelvic osteolysis in the Gorham–Stout syndrome. Int Orthop 1990; 14(4): 361-6.

Kurijama D K, McElligott S C, Glaser D W, Thompson K S. Treatment of Gorham–Stout disease with zoledronic acid and interferon-α: a case report and literature review. J Pediatr Hematol Oncol 2010; 32(8): 579-84.

Li M-H, Zhang H-Q, Lu Y-J, Gao P, Huang H, Hu Y-C, et al. Successful management of Gorham–Stout disease in scapula and ribs: a case report and literature review. Orthop Surg 2018; 10(3): 276-80.

Liu Y, Zhong D-R, Zhou P-R, Lv F, Ma D-D, Xiao W-B, et al. Gorham–Stout disease: radiological, histological, and clinical features of 12 cases and review of literature. Clin Rheumatol 2016; 35(3): 813-23.

Liu S, Zhou X, Song A, Kong X, Wang Y, Liu Y. Successful treatment of Gorham–Stout disease in the spine by vertebroplasty with cement augmentation. Medicine 2018; 97(29): e11555-6.

Ludwig K F, Stone L, Cederberg K B, Silva A T, Delling M. A new case and review of chylothorax in generalized lymphatic anomaly and Gorham–Stout disease. Lymphology 2016; 49(2): 73-84.

Mignogna M D, Fedele S, Russo Lo L, Ciccariello R. Treatment of Gorham’s disease with zoledronic acid. Oral Oncol 2005; 41(7): 477-50.

Mo A Z, Trenor C C, Hedequist D J. Sirolimus therapy as perioperative treatment of Gorham–Stout disease in the thoracic spine: a case report. JBJS Case Connect 2018; 8(3): e70.

Möller G, Priormel M, Amling M, Werner M, Kulhimey A S, Delling G. The Gorham–Stout syndrome (Gorham’s massive osteolysis). J Bone Joint Surg Br 1999; 81-B(3): 501-6.

Patel D V. Gorham’s disease or massive osteolysis. Clin Med Res 2005; 3(2): 65-74.

Patrick J H. Massive osteolysis complicated by chylothorax successfully treated by pleurodesis. J Bone Joint Surg Br 1976; 58-B(3): 347-9.

Ramaroli D A, Cavarzere P, Cheli M, Provenzi M, Barillari M, Rodella G, et al. A child with early-onset Gorham–Stout disease complicated by chylothorax: near-complete regression of bone lesions with interferon and bisphosphonate treatment. Horm Res Paediatr 2019; 10: 1-5.

Rauth G, Gross M. Disappearing bone disease (Gorham–Stout disease): report of a case with a follow-up of 48 years. Eur J Med Res 1997; 2(10): 425-7.

Reid I R. Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. Skeletal Radiol 2011; 40(9): 1191-6.

Tunn P U, Pommraenke D, Goering U, Hohenberger P. Functional outcome after endoprosthetic limb-salvage therapy of primary bone tumours: a comparative analysis using the MSTS score, the TESS and the RNL index. Int Orthop 2008; 32(5): 619-25.

Tirma S, Gigante C, Scapinelli R. A 20-year follow-up study of a case of surgically treated massive osteolysis. Clin Orthop Relat Res 1990; (250): 297-302.

Wessel J H, Dodson T B, Zavras A I. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 2008; 66(4): 625-31.

Yerganyan V V, Body J J, De Saint Aubain N, Gebhart M. Gorham–Stout disease of the proximal fibula treated with radiotherapy and zoledronic acid. J Bone Oncol 2015; 4(2): 42-6.

Zanelli M, Zizzo M, Martino G, Bisagni A, De Marco L, Ascani S. Bone marrow biopsy disclosing a rare osteolytic disorder: Gorham–Stout syndrome. Int J Surg Pathol 2020; 28(1): 76-7.